| INTRODUCTION
Chronic intestinal pseudo-obstruction (CIPO) is a rare and intractable chronic digestive disease in which clinical symptoms of intestinal obstruction appear without mechanical cause. [1] [2] [3] [4] CIPO patients often remain unrecognized for a long time before a correct diagnosis is obtained and almost invariably undergo repeated, ineffective, and potentially dangerous surgical procedures. 4, 5 To improve this miserable situation, in 2012 our group proposed clear diagnostic criteria for CIPO, and demonstrated that the criteria are useful in clinical practice with a high sensitivity of 86.3% in Japanese cases. 6 More recently, we reported that cine magnetic resonance imaging (cine-MRI), which allows for the dynamic evaluation of organ function with high temporal and spatial resolution, can accurately distinguish CIPO from irritable bowel syndrome (IBS), which shows similar abdominal symptoms but has an exceptionally high prevalence of 5%-10% of the world's population. 7 Chronic intestinal pseudo-obstruction can affect the entire gut from the esophagus to the rectum, but predominantly affects the small intestine. Sustained increased intraluminal pressure often causes small intestinal malabsorption and bacterial translocation, leading to malnutrition and bloodstream infection. Important aspects of the medical approach for CIPO are to improve nutritional status and reduce abdominal symptoms. 8 Clinically, home parenteral nutrition (HPN) and decompression therapy are required in most patients. 9 However, conventional decompression methods (eg, trans-nasal small intestinal tube) assume a large burden for patients in that it causes extensive nasal pain and requires near-perpetual hospitalization. Furthermore, palliative ileostomy, a surgical option in cases unresponsive to medical therapy, 10, 11 is more invasive and is problematic because it cannot control the drainage volume and can cause excess drainage and dehydration. To date such issues have remained unresolved with respect to the treatment of this disease.
As already mentioned, the proposed diagnostic criteria and emergence of cine-MRI have made the diagnosis of CIPO easier and faster than before. However, little is established concerning the treatment method, and this is the urgent problem to resolve in current clinical practice.
Percutaneous endoscopic gastrostomy (PEG) is a method commonly used to access the gastrointestinal tract for long-term home enteral nutrition in patients with neurogenic deglutition and stenosis of the upper gastrointestinal tract caused by malignant tumors, although aspiration pneumonia is a prevailing complication that leads to high mortality. Gastro-jejunostomy tube insertion through the PEG (PEG-J) is often performed to prevent aspiration pneumonia in highrisk patients. 12 In addition to administration of enteral nutrition, PEG/ PEG-J is used for decompression in patients with malignant bowel diseases. A recent study reported that elimination of nasal intubation can be achieved in most of these patients in combination with a transgastrostomy intestinal tube insertion. 13 We hypothesized that PEG-J can also provide effective intestinal decompression, help reduce the abdominal symptoms, and improve the nutritional status in CIPO patients. To evaluate the possibility of a novel decompression therapy for this intractable disease, we conducted a pilot study and assessed the efficacy and safety of PEG-J decompression therapy in patients with CIPO.
| METHODS

| Study design
Pilot cohort study.
| Ethics
The Institutional Ethics Committee approved this interventional study, and written informed consent was obtained from all subjects before entering the study. The clinical trial number is UMIN000017574.
| Eligibility
We selected severe CIPO patients who were refractory to medication therapies including prokinetic agents, laxatives, probiotics, and herbal medicine, and at least once required nasogastric tube (NG tube) or transnasal small intestinal tube insertion for intestinal decompression in our institution, an expert center in Japan. The inclusion criteria were as follows: (iii) dilatation of the bowels with air-fluid levels on abdominal X-ray and/or computed tomography (CT) imaging; and (iv) the exclusion of any organic obstruction of the intestinal lumen.
2.
Patients in whom malnutrition was observed and small intestinal decompression appeared to be necessary.
3.
Patients from whom written informed consent was obtained.
The exclusion criteria were as follows:
1.
Patients with organic digestive tract disease.
2.
Patients with current or past history of malignant disease.
Key Points
• Chronic intestinal pseudo-obstruction (CIPO) is an extremely severe motility disorder and appropriate intestinal decompression is required, but conventional treatment is invasive and painful. A less invasive and tolerable new decompression method is urgently needed.
• Percutaneus endoscopic gastro-jejunostomy (PEG-J) was well tolerated in all patients and improved both abdominal symptoms and nutritional status without severe complications.
• Percutaneus endoscopic gastro-jejunostomy (PEG-J) is a minimally invasive, tolerable and have a potential to be a novel decompression method that is available at home.
3.
Patients with current other digestive diseases.
4.
Patients with psychiatric disorders.
5.
Patients judged inappropriate for the trial by investigators. Table 1 .
| CIPO patients
| PEG-J procedure
At first, PEG placement with a tube caliber of 24F was carried out by the introducer method (Direct Ideal PEG Kit; Olympus, Tokyo, Japan). In the case where the distended small bowel loops were interposed between the stomach wall and the abdominal wall, preceding decompression was performed using a trans-nasal small intestinal tube. Once PEG placement was made, the stomach wall was fixed to the abdominal wall for 7 days to obtain a stable fistula. After 7 days of gastropexy, a gastro-jejunostomy tube with a caliber of 24F and length of 60 cm was inserted through the PEG fistula (PEG-J) under X-ray fluoroscopy immediately after removal of the PEG button (GB Jejunal Button; Fuji Systems, Tokyo, Japan) ( Figure 1 ).
| Data sampling and statistical analysis
We investigated the number of the days with any abdominal symptoms in a month (NODASIM) for the comprehensive evaluation of subjective symptoms, and body mass index (BMI) and serum albumin level (Alb) for the assessment of objective nutritional status, then compared these variables pre-PEG-J and post-PEG-J in each patient. Post-PEG-J assessment was performed 3 months after the procedure with administration of the medication drugs allowed in all patients. Use of IVH was also permitted when necessary in two patients as well as pre-PEG-J.
NODASIM was defined as the number of the days with at least one of the following symptoms in the last 30 days: abdominal pain, distension, nausea, and vomiting. All patients kept symptom diaries and showed them at the outpatient visit every month, and we measured NODASIM from the diaries. In addition, the volume of the entire small intestine calculated by the volume analyzer SYNAPSE VINCENT (Fujifilm Medical, Tokyo, Japan) was also compared pre-and post-treatment. These calculations were carried out using three-dimensional CT (3DCT) images.
Pre-PEG-J 3DCT images were taken after a 12-hours cessation of any eating and drinking in the symptomatic period, and post-PEG-J images were taken after a 12-hours fast and >12 hours after last drainage. All data obtained were statistically analyzed using Wilcoxon's signed-rank test. A P value of .05 or less was considered as significant.
| RESULTS
Percutaneous endoscopic gastrostomy placement and PEG-J tube insertion was performed without major procedure-related complications and was well tolerated by all patients. Also, oral intake was well maintained or improved in all patients after the procedure.
Comparison of the pre-and postprocedure NODASIM, BMI, and Alb values is shown in Table 2 and Figure 2 . Of the seven patients, the Conversely, severe reflux esophagitis (case 1) and chemical dermatitis around the PEG-J fistula (case 2) was observed during follow-up ( Figure 5A and B). In case 1, administration of a proton-pump inhibitor (PPI) and refinement of the meal form (semisolid meals) have attenuated the reflux symptoms ( Figure 5C ), and in case 2, ointment therapy has been highly successful ( Figure 5D ). Outpatient follow-up was possible in both patients. No ulcer formation and perforation due to the tube placement was observed at 1 year after PEG-J introduction in all patients.
| DISCUSSION
In our seven patients, a significant decrease of NODASIM and a significant increase of BMI/Alb were observed after PEG-J induction,
The PEG button was removed and an ultrathin endoscope was inserted through the fistula into at least the second portion of the duodenum or beyond, and a guide wire was introduced through the working channel of the endoscope into the upper jejunum. Thereafter, the endoscope was carefully removed with the guide wire left in place. The PEG-J tube was inserted along the guide wire and placed into the upper jejunum, after which the guide wire was removed and the total volume of the small intestine was largely reduced as well as gas volume and fluid volume, although there was no statistically significant difference.
We used NODASIM as the comprehensive indicator of subjective symptoms, and BMI and serum Alb level as indicators of objective nutritional status. In general, the clinical features are dominated by severe abdominal pain and distension, nausea, and vomiting in CIPO patients.
However, the frequency and strength of these symptoms vary largely between patients and even within the same patient. 4 Taking into account the inter-and intrapatient variance of the symptoms, it is inappropriate to adopt the extent of abdominal symptoms in a specific day as a clinical endpoint. The number of days with symptoms within a certain period thus appealed to us as a better endpoint in this study, so we selected the number of days with any abdominal symptoms in 1 month. As a result, PEG-J improved both abdominal symptoms and nutritional status in all of the patients.
Furthermore, we compared the entire small intestinal volume before and after the PEG-J procedure to assess the decompression efficacy more objectively. In general, mechanical obstruction and motility disorders of the small intestine, including CIPO, cause small intestinal bacterial overgrowth (SIBO). In humans, hydrogen and methane are exclusively produced by intestinal bacteria, and a large amount of gas production occurs in the small intestine under SIBO conditions. 14 In CIPO patients, because the peristaltic motility of the small intestine is F I G U R E 2 Pre-and postprocedural changes in each variable F I G U R E 3 Marked improvement of the intestinal distension is observed in the plain abdominal radiograph and abdominal CT. PEG-J makes the acute flexure mild and obtuse (dotted line on coronal plane CT). 3DCT also shows the small intestine to be well decompressed by the PEG-J tube highly disturbed, SIBO develops and the production of these insoluble gases in the small intestine may be strongly accelerated. In the distended bowel loops, insoluble gas is stagnant above the intestinal fluid concomitant with gravity, and the stagnant gas cannot be propelled forward efficiently because of severely impaired motility. Excessive gas and fluid stagnation cause severe abdominal distension in most cases. In this study, a significant reduction in the small intestinal volume was not obtained, maybe because of the small sample size and >12 hours period without drainage before 3DCT scan in post-PEG-J evaluation; however, PEG-J seemed to be effective for removal of the intestinal fluid as well as the stagnant gas, taking into account the fact that subjective symptoms (NODASIM) had significantly improved.
Effective drainage of the intraluminal gas seems more difficult than drainage of the intraluminal fluid because the gas tends to be stagnant in a certain location in the small intestine. Specifically, the stagnant gas in the distal jejunum or ileum might not be discharged sufficiently by a PEG-J with a length of 60 cm. A longer PEG-J tube may have the Conversely, reflux esophagitis (n=1) and chemical dermatitis (n=1) were identified during the follow-up. These adverse events may be a result of delayed emptying of the gastric contents due to sub-occlusion of the pyloric ring by the inserted tube. Fortunately, these acid reflux symptoms improved after initiation of conservative therapies.
Several limitations exist in this study. First is the lack of a breath test and manometric studies. Assuredly a hydrogen breath test can assess the degree of SIBO, 16 and manometry allows evaluation of the pattern of impaired intestinal peristalsis in CIPO patients. However, these tests are relatively challenging for routine clinical practice because their reproducibility and specificity are relatively low and available only in a limited number of institutions. In this study, we were unable to perform these tests in our Japanese population. The second limitation is the unblinded study design. Patients' symptom diaries could not be recorded under blinded condition because of the obvious presence of PEG-J and it may be an important source of bias. However, BMI/Alb and small intestinal volume calculated by the volume analyzer are the objective data that appear not to be influenced by unblinding.
The third limitation is that we could not compare the decompression effect directly between PEG-J therapy and conventional trans-nasal tube method (ie, NG tube or trans-nasal small intestinal tube 18 Also, ileostomy is effective in most of the patients, 11 but more invasive and problematic because it cannot control the drainage volume. Compared to these methods, PEG-J is a relatively simple and safe procedure that provides a good access to the intestinal contents, and allows patients themselves to control the drainage volume. The fourth limitation is the small number of patients and a single arm study design. A previous epidemiologic study estimated the total number of CIPO patients treated throughout Japan during a year to be 1148, and reported the very low prevalence of less than 1 per 100 000 individuals. 19 Therefore, as CIPO is a very rare disease, the collection of sufficient patients was difficult and we had to conduct this study without controls who did not receive PEG-J. This is a potential major bias in our study. However, as our institution is the most familiar with CIPO in Japan and most often experiences adult cases, at present this represents the largest collection of data thus far in our country.
In conclusion, PEG-J decompression is a minimally invasive, tolerable method and improves both abdominal symptoms and nutritional status in CIPO patients. Although sufficient attention should be paid to acid reflux symptoms, PEG-J has the potential to be a novel decompression therapy for CIPO, available at home. Accumulation of more CIPO patients, long-term observation, and the development of cosmetically acceptable and longer more effective tubes are future challenges.
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